Souhaitez-vous accéder aux communiqués récents ?

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy.

Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).

Longeveron CEO Wa’el Hashad will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.

Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.

Longeveron selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.

Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.

Longeveron issues letter to shareholders highlighting corporate strategy, recent progress and 2025 key priorities and goals.

Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.